Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

Article Virology

The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells

Shutoku Matsuyama et al.

Summary: The study found that the inhaled corticosteroid ciclesonide can inhibit the replication of coronaviruses, including SARS-CoV-2, with potential use in treating COVID-19. Ciclesonide also successfully suppressed the replication of 15 resistant mutants, making it a promising broad-spectrum antiviral drug.

JOURNAL OF VIROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

Sanjay Ramakrishnan et al.

Summary: The study found that early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and accelerated recovery time in patients with early COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Ly-Mee Yu et al.

Summary: The study found that inhaled budesonide can reduce recovery time and potentially decrease the risk of hospital admissions or deaths among high-risk COVID-19 patients in the community.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Patrick R. Lawler et al.

Summary: This study showed that therapeutic-dose anticoagulation with heparin in non-critically ill patients with Covid-19 increased the likelihood of survival to hospital discharge and reduced the need for cardiovascular or respiratory organ support compared to usual-care thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Jean-Claude Tardif et al.

Summary: The study aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. Among patients with PCR-confirmed COVID-19, colchicine led to a lower rate of the composite of death or hospital admission than placebo.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Microbiology